Dyadic to Present at Upcoming Industry and Investor Events in November
November 07 2022 - 8:30AM
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:
DYAI), a global biotechnology company focused on building
innovative microbial platforms to address the growing demand for
global protein production and unmet clinical needs for effective
and affordable biopharmaceutical products for human and animal
health, today announced that its management and representatives
will participate in the following upcoming industry and investor
events in November 2022:
RAFT® 14 Conference (Recent Advances in
Fermentation Technology)Hosted by the Society for Industrial
Microbiology and BiotechnologyNovember 6-9, 2022Caribe Royale Hotel
– Orlando, FLPresenter: Mark EmalfarbPresentation Time: 1:00 PM ET,
Tuesday, November 8, 2022Registration Link: RAFT® 14
BARDA Industry Day 2022 Virtual EventNovember
15-16, 2022Website: BID2022
INV€$TIVAL Showcase™November 14, 2022 Old
Billingsgate, London, UKPresenter: Mark EmalfarbPresentation Time:
12:00 PM GMTRegistration Link: INVESTIVAL SHOWCASE
Jefferies London Healthcare ConferenceNovember
16-19, 2022Waldorf Hilton (Aldwych) London, UKWebsite: Jefferies
London Healthcare Conference
Dyadic management will be available during these
events for one-on-one meetings. Interested parties may request a
one-on-one meeting at jlavalley@dyadic.com or contact Dyadic at
(561) 743-8333.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company committed to building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products for human and animal
health.
Dyadic's gene expression and protein production
platforms are based on the highly productive and scalable
fungus Thermothelomyces heterothallica (formerly
Myceliophthora thermophila). Our lead technology, C1-cell
protein production platform, is based on an industrially proven
microorganism (named C1), which is currently used to speed
development, lower production costs, and improve performance of
biologic vaccines and drugs at flexible commercial scales for the
human and animal health markets. Dyadic has also developed the
Dapibus™ filamentous fungal based microbial protein production
platform to enable the rapid development and large-scale
manufacture of low-cost proteins, metabolites, and other biologic
products for use in non-pharmaceutical applications, such as food,
nutrition, and wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please visit
www.dyadic.com.
Safe Harbor Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International's expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of our clinical
trial application and our ability to secure commercial agreements
and take advantage of other business opportunities. Actual events
or results may differ materially from those in the forward-looking
statements because of various important factors, including those
described in the Company's most recent filings with the SEC. Dyadic
assumes no obligation to update publicly any such forward-looking
statements, whether because of new information, future events or
otherwise. For a more complete description of the risks that could
cause our actual results to differ from our current expectations,
please see the section entitled "Risk Factors" in Dyadic's annual
reports on Form 10-K and quarterly reports on Form 10-Q filed with
the SEC, as such factors may be updated from time to time in
Dyadic's periodic filings with the SEC, which are accessible on the
SEC's website and at www.dyadic.com.
Contact:Dyadic International,
Inc.Ping W. RawsonChief Financial OfficerPhone: (561)
743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024